RC88
Solid Tumors (MSLN+)
Phase 1/2Active
Key Facts
About RemeGen
A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.
View full company profileSolid Tumors (MSLN+)
A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.
View full company profile